SCHEMBL901064

SCHEMBL901064

O=C1NN=CC1=NNc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
GFER P55789 2/20 0.41
KMT2A Q03164 6/20 0.39
GAA P10253 6/20 0.39
MEN1 O00255 5/20 0.39
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 2/20 0.39
ALOX12 P18054 1/20 0.39
MCL1 Q07820 1/20 0.39
HTT P42858 1/20 0.39
DEPTOR Q8TB45 1/20 0.38
TDP1 Q9NUW8 4/20 0.36
CYP1A1 P04798 1/20 0.36
TSHR P16473 1/20 0.36
CYP1B1 Q16678 1/20 0.36
TAAR1 Q96RJ0 3/20 0.33
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
KDM4E B2RXH2 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL16212974 0.92 ALDH1A1 (0.37) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL6977827 0.68 DEPTOR (0.53) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL14003218 0.66 ALDH1A1 (0.43) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL27873782 0.66 ALDH1A1 (0.54) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL4596033 0.65
SCHEMBL6977823 0.64 ALDH1A1 (0.44) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL922326 0.63 DEPTOR (0.39) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL922327 0.63 DEPTOR (0.39) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL26514432 0.63 ALDH1A1 (0.51) ALDH1A1GFERKMT2AGAAMEN1
SCHEMBL341192 0.62 ALDH1A1 (0.39) ALDH1A1GFERKMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680215-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX Management LLC (US) 2026-01-21 EP claimed
WO-2024196822-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX MANAGEMENT LLC (US) 2024-09-26 WO claimed
US-20240033284-A1 METHOD OF ADMINISTRATION AND TREATMENT DYVE BIOSCIENCES, INC. 2024-02-01 US claimed
EP-4680215-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX Management LLC (US) 2026-01-21 EP disclosed
WO-2024196822-A1 COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES MDX MANAGEMENT LLC (US) 2024-09-26 WO disclosed
CN-115379859-A Transdermal osmotic agent formulation 黛芙生物科学公司 2022-11-22 CN disclosed
US-20220323344-A1 TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS DYVE BIOSCIENCES, INC. 2022-10-13 US disclosed
EP-4069210-A1 TRANSDERMAL PENETRATION BY MODULATING EPITHELIAL JUNCTIONS Dyve Biosciences, Inc. (US) 2022-10-12 EP disclosed
CN-114929208-A Transdermal penetration by modulation of epithelial junctions 黛芙生物科学公司 2022-08-19 CN disclosed
EP-3986464-A1 TRANSDERMAL PENETRANT FORMULATIONS Dyve Biosciences, Inc. (US) 2022-04-27 EP disclosed
US-20220105062-A1 TRANSDERMAL PENETRANT FORMULATIONS DYVE BIOSCIENCES, INC. 2022-04-07 US disclosed
WO-2012041524-A1 HYDRAZONOPYRAZOLONES AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) 2012-04-05 WO disclosed